Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

By A. Rush, Madhukar H. Trivedi, S. Wisniewski, A. Nierenberg, J. Stewart, D. Warden, G. Niederehe, M. Thase, Philip W. Lavori, B. Lebowitz and 6 more. American Journal of Psychiatry, 2006

2,735 citations recorded by the source corpus.

Subfields: Pharmacology

View Paper: https://www.semanticscholar.org/paper/4a4f8897fcefbe2ee05aad30e6621233d118f196

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

Citations in the corpus

Robust Hybrid Learning for Estimating Personalized Dynamic Treatment Regimens (2016, background): “…are useful in treating many complex chronic disorders such as substance dependence, attention deﬁcit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), major depressive disorder (MDD), and schizophrenia (Schneider et al., 2003; Rush et al., 2004, 2006; Oslin, 2005; Jones, 2010).”
Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications (2013, background): “Moreover, approximately 30% of depressed patients fail to respond to standard antidepressant treatments (Rush et al., 2006), and these patients have been shown to exhibit increased inflammatory cytokines (Sluzewska et al.”
Role of neuroinflammation in neurodegenerative diseases (Review) (2016, neutral): “Although biological mechanisms of depression are poorly understood, conventional antidepressant treatments procuring beneficial effects were unsuccessful on one‑third of depressed patients due to the inflammation that contributed to treatment resistance (48).”
Handbook of Dynamic Psychotherapy for Higher Level Personality Pathology (2007, background): “Many patients will require ongoing adjustment of medication regimen in order to optimize treatment of depressive illness (Rush et al. 2006).”
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression (2012, neutral): “The major findings of this study are that (1) the antidepressant effect of ketamine is evident very early in the course of treatment, (2) ketamine exerts a broad-spectrum effect on individual symptoms of depression, and (3) rapid response to the first infusion is highly predictive of a sustained res”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (2015, background): “These remission rates can be compared with those demonstrated by the STAR*D study which showed that the remission rates for the first, second, third and fourth treatment steps were 36.8%, 30.6%, 13.7% and 13% respectively (Rush et al., 2006).”
Computational psychiatry as a bridge from neuroscience to clinical applications (2016, background): “In depression, for example, although up to three quarters of patients will eventually respond to an antidepressant, two thirds require multiple treatment trials before responding 53 .”
Machine Learning for Precision Psychiatry: Opportunities and Challenges. (2017, background): “4 This is because of the unfortunate normal case of trial-and-error treatment with psychotropic drugs and other types of treatment for many mental diseases (17).”
Help-Seeking and Access to Mental Health Care in a University Student Population (2007, background): “with mental health care and the fact that even with high-quality care a large proportion of people do not achieve full remission.(44) Third, over 90% of students had health insurance, but about half had no idea if they had insurance coverage for mental health visits, and the majority of the rest wer”
Major depression. (2014, background): “Switching antidepressants instead of augmenting at this stage had lower efficacy with 13% remission with mirtazapine and 20% with nortriptyline.(35) By the fourth attempt at a medication change in the study, adding or changing medications to this highly refractory group had low remissions rates of 7”